Comunicato OVID
Estratto con note curato dalla ref. scientifico ORSA dott.ssa Ilaria TonazziniIstituto Nanoscienze-CNR @NEST (National Enterprise for nanoScience and nanoTechnology), Pisa del report OVID pubblicato al link:
https://www.biopharmadive.com/news/ovids-angelman-syndrome-drug-shows-mixed-results-in-phase-2/529433/ ...